SyntheticMR's Innovative SyMRI Software Receives Regulatory Approval in Malaysia

SyntheticMR announced today that their quantitative imaging software solution SyMRI has received regulatory approval in Malaysia and can now be sold and distributed in this market.

"We are very excited to bring our innovative SyMRI software to the Malaysian market," says Deepak Sharma, Head of Sales in India and South East Asia. "Our entrance into this market opens the door to many incredible opportunities for SyntheticMR. We are looking forward to working with new healthcare providers to support a faster hospital workflow, greater diagnostic confidence, and improved patient satisfaction."

SyMRI provides multiple contrast weighted images and quantitative information about the patient in a single 5-minute scan, enabling users to speed up their imaging workflow and add objective decision support to their practice.

For additional information, please contact Ulrik Harrysson, CEO, SyntheticMR AB, +46 70 529 29 87 ulrik.harrysson@syntheticmr.com or Johanna Norén, CFO och Head of Investor Relations, SyntheticMR AB, +46 70 619 21 00 johanna.noren@syntheticmr.com.

SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI®, delivering multiple, adjustable contrast images and quantitative data from a single 5-minute scan. The SyMRI product is available in different packages. SyMRI NEURO delivers multiple contrast images, tissue segmentations and quantitative data on the brain. SyMRI KNEE and SyMRI SPINE provides multiple contrast images and quantitative data for knee and spine anatomies. SyMRI NEURO is CE-marked and FDA 510(k) cleared and SyMRI KNEE and SyMRI SPINE is CE-marked. SyMRI is a registered trademark in Europe and the USA. SyntheticMR is listed on the Spotlight Stock Market Exchange in Stockholm, Sweden. For more information, visit www.syntheticmr.com.